4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable...
Source: marketscreener.com